Clinical trials: Carbapenem-Resistant Enterobacteriaceae Infection
Carbapenem-Resistant Enterobacteriaceae Infection
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against…
- Trial name
- NCT05850871
- Testing
- CAZ/AVI plus Aztreonam, Conventional treatment
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Qianfoshan Hospital
Infectious Disease
Temocillin in ESBL-Enterobacteriaceae Infections
Because of the increasing incidence of infections with multi-drug resistant enterobacteriaceae, we need alternative treatments to spare carbapenems.
- Trial name
- TMO2016 (NCT05413772)
- Testing
- Temocillin
- Where
- 2 sites in France
- Volunteers
- 29 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carbapenem-Resistant Enterobacteriaceae Infection
Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly identified in children in China. Pediatric intensive care unit (PICU) is the high-risk area.
- Trial name
- NCT04535661
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Children's Hospital of Fudan University
Carbapenemase-producing Enterobacteriaceae Infection
Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae
Infections caused by carbapenemase-producing Enterobacteriaceae are frequent and often associated with high rates of mortality. Colonized patients are at increased risk of infection for these microorganisms.
- Trial name
- KAPEDIS (NCT04760665)
- Testing
- Fecal microbiota transplantation
- Where
- Spain
- Volunteers
- 2 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Carbapenem-Resistant Enterobacteriaceae Infection, Pneumonia - Bacterial
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.
Study Design: A randomized, open-label, parallel-group clinical trial comparing the efficacy and safety of jet nebulization versus vibrating mesh nebulization of sulfate polymyxin B in mechanically ventilated patients with…
- Trial name
- NCT07086391
- Testing
- Polymyxin B Sulfate 25mg Jet Nebulization / Vibrating Mesh Nebulization
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Fujian Medical University Union Hospital
Enterobacteriaceae Infections, Multi-antibiotic Resistance
FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae
Rates of antimicrobial resistance are increasing worldwide. There is increasing evidence that physiological gut microbiota is a large reservoir of antibiotic-resistance genes.
- Trial name
- FMT-CRE (NCT04759001)
- Testing
- Donor FMT
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Infection Due to Resistant Organism
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Transplant patients are at increased risk of colonization and infection with Multidrug Resistant Organisms (MDROs) due to medications that modify their immune systems, increased healthcare and antibiotic exposure, and surgical…
- Trial name
- PREMIX (NCT02922816)
- Testing
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Carbapenemase-Producing Enterobacteriaceae
Incidence and Risk Factors for Developing Infections in Patients Colonized by CP-KPC
The worldwide increase in the rate of infections due to multidrug-resistant bacteria is considered a major public health problem.
- Trial name
- KPC (NCT05492539)
- Where
- Argentina
- Volunteers
- 500 people
- Sponsor
- Hospital Italiano de Buenos Aires
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Enterobacteriaceae Infections, Community-Acquired Infections
Community-associated Highly-Resistant Enterobacterales
This is a prospective multi-center study. Bacterial isolates from hospitalized patients with CA-HRE will be compared to those from hospitalized patients with healthcare-associated HRE (HA-HRE).
- Conditions
- Enterobacteriaceae Infections, Community-Acquired Infections, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- COCARE (NCT03924934)
- Where
- United States
- Volunteers
- 2,172 people
- Sponsor
- University of North Carolina, Chapel Hill
Carbapenem-Resistant Enterobacteriaceae Infection, Vancomycin-Resistant Enterococcal Infection
The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
The purpose of this study is to assess the effect of fecal microbiota transplantation for the decolonization of carbapenem-resistant Enterobacteriaceae or vancomycin-resistant Enterococci in the gut.
- Trial name
- NCT04583098
- Testing
- fecal microbiota transplantation
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Antimicrobial Drug Resistance, Antibiotic Resistant Infection
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or…
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- DYNAMITE (NCT06258551)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Infection With Beta-lactam Resistance in Enterobacteriaceae
Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region
Upon penicillins' introduction, inactivation of beta- lactam antibiotics by enzymes produced by bacteria was demonstrated. Until recently, carbapenems were a relatively spared subclass by these enzymes which makes the molecules…
- Trial name
- CARBAFREST (NCT02803710)
- Testing
- Microbiological study
- Where
- France
- Volunteers
- 315 people
- Sponsor
- CHU de Reims
Blood Stream Infections, Ventilator Associated Pneumonia
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
RAPID is an investigator initiated Phase 4, multinational, multicentre, open-label, randomised controlled superiority trial evaluating the clinical impact of rapid microbiological diagnostics combined with antimicrobial…
- Conditions
- Blood Stream Infections, Ventilator Associated Pneumonia, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- RAPID (NCT05979545)
- Testing
- Rapid Diagnostics
- Where
- 21 sites in India, Malaysia and 5 more
- Volunteers
- 1,526 people
- Sponsor
- National University of Singapore
Infections Resistant to Multiple Drugs, Bacterial Infections
Multi-Drug Resistant Organism Network
This study is specifically designed to provide observational data which can be used to help in the design of future randomized clinical trials on both therapeutics and diagnostics for MDRO infections.
- Trial name
- MDRO Network (NCT03646227)
- Testing
- Standard of Care
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 6,496 people
- Sponsor
- Duke University
Antibiotic Resistant Infection, Carbapenem-Resistant Enterobacteriaceae Infection
Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals
Carbapenem resistant Enterobacteriaceae (CRE) colonization of patients discharged from hospitals is a source of transmission to the community.
- Trial name
- I-CRECT (NCT05871476)
- Testing
- Hospital Cohort Care Intervention at the hospital, , Household Education Communication Hygiene Intervention, Livestock Antibiotic Intervention
- Where
- Vietnam
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Hanoi University of Public Health
Urinary Tract Infection, Complicated, Acute Pyelonephritis
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
A multi-center, retrospective study of cases of serious bacterial infections including complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP), Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Acquired…
- Conditions
- Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02420366
- Where
- 22 sites in United States, Greece and 2 more
- Volunteers
- 257 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Healthcare-Associated Infections (HAIs), Carbapenem-Resistant Enterobacteriaceae Colonization
Correlation Between Carbapenemase-Producing Enterobacterales Load, Environmental Contamination, and Transmission in Critical Care Units
Carbapenemase-producing Enterobacterales (CPE) are multidrug-resistant bacteria that can colonize the gastrointestinal tract of hospitalized patients and spread within intensive care units (ICUs).
- Conditions
- Healthcare-Associated Infections (HAIs), Carbapenem-Resistant Enterobacteriaceae Colonization, Antimicrobial Resistance (AMR)
- Trial name
- CPE-Load ICU S (NCT07685132)
- Where
- Argentina
- Volunteers
- 60 people
- Sponsor
- Hospital Italiano de Buenos Aires
Carbapenem-Resistant Enterobacteriaceae
Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.
The primary purpose of this clinical investigation is to establish the performance of the GenePOC Carba assay on the revogene. This will be achieved by comparing the test to a conventional method for detection of Carbapenemase…
- Trial name
- NCT03680898
- Testing
- Rectal swab collection
- Where
- 3 sites in United States, Canada
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Carbapenem-resistant Enterobacteriaceae
The Population Pharmacokinetics Study of Tigecycline and Pharmacokinetics- Pharmacodynamics Index in Patients With Carbapenem Resistant Enterobacteriaceae Bloodstream Infection
Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. Patients who were infected caused by CRE bloodstream infection were high mortality up to 40%.
- Trial name
- NCT06049771
- Testing
- Collect blood sample
- Where
- Thailand
- Volunteers
- 72 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital